E. Salminen
Department of Oncology and Radiotherapy
Turku University Hospital
Finland
Name/email consistency: high
- Docetaxel, a promising novel chemotherapeutic agent in advanced breast cancer. Salminen, E., Bergman, M., Huhtala, S., Jekunen, A., Ekholm, E. Anticancer Res. (2000)
- Second cancers in patients with brain tumours--impact of treatment. Salminen, E., Pukkala, E., Teppo, L. Eur. J. Cancer (1999)
- Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. Salminen, E., Bergman, M., Huhtala, S., Ekholm, E. J. Clin. Oncol. (1999)









